Aliskiren, a direct renin inhibitor newly developed, was reported to have therapeutic effect on hypertension [15,16], stroke [43] and hypertrophy [17], but fail to attenuate LV remodelling in high-risk post-MI patients who had already received standard therapy including one RAS inhibitor, which suggested that dual RAS blockade with Aliskiren would not provide additional benefit to post-MI patients [44]. This evidence concerns the gene REN and Stroke.